Transgenic expression of full-length 2′,5′-oligoadenylate synthetase 1b confers to BALB/c mice resistance against West Nile virus-induced encephalitis  by Simon-Chazottes, Dominique et al.
Virology 417 (2011) 147–153
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roTransgenic expression of full-length 2′,5′-oligoadenylate synthetase 1b confers to
BALB/c mice resistance against West Nile virus-induced encephalitis
Dominique Simon-Chazottes a,d, Marie-Pascale Frenkiel b, Xavier Montagutelli a,d, Jean-Louis Guénet c,
Philippe Desprès b, Jean-Jacques Panthier a,d,⁎
a Mouse Functional Genetics, Institut Pasteur, Paris, France
b Flavivirus–Host Molecular Interactions, Institut Pasteur, Paris, France
c Department of Developmental Biology, Institut Pasteur, Paris, France
d Centre National de la Recherche Scientiﬁque, Unité de Recherche Associée 2578, Paris, France⁎ Corresponding author at: Institut Pasteur, Mouse f
Docteur Roux, 75015 Paris, France. Fax: +33 1 4568 86
E-mail address: panthier@pasteur.fr (J.-J. Panthier).
0042-6822/$ – see front matter © 2011 Elsevier Inc. Al
doi:10.1016/j.virol.2011.05.018a b s t r a c ta r t i c l e i n f oArticle history:
Received 4 March 2011
Accepted 31 May 2011
Available online 17 June 2011
Keywords:
Flavivirus
Mouse
Transgenesis
OAS
Encephalitis
Inbred strains
Innate resistance
Genetic deﬁciency
Antiviral effect
Genetic determinantSusceptibility of inbred strains to infection with West Nile virus (WNV) has been genetically associated with
an arginine-to-a nonsense codon substitution at position 253 (R253X) in the predicted sequence of the
murine 2′,5′-oligoadenylate synthetase 1B (OAS1B) protein. We introduced by transgenesis the Oas1b cDNA
from MBT/Pas mice carrying the R253 codon (Oas1bMBT) into BALB/c mice homozygous for the X253 allele
(Oas1bBALB/c). Overexpression of Oas1bMBT mRNA in the brain of transgenic mice prior and in the time course
of infection provided protection against the neuroinvasive WNV strain IS-98-ST1. A 200-fold induction of
Oas1bMBT mRNA in the brain of congenic BALB/c mice homozygous for a MBT/Pas segment encompassing the
Oas1b gene was also efﬁcient in reducing both viral growth and mortality, whereas a 200-fold induction of
Oas1bBALB/c mRNA was unable to prevent virally-induced encephalitis, conﬁrming the critical role of the
R253X mutation on Oas1b activity in live mice.unctional Genetics, 25 rue du
34.
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
West Nile virus (WNV) is a positive-sense, single-stranded RNA
ﬂavivirus transmitted by mosquitoes that infects a wide range of
vertebrate hosts and causes severe illness in humans, including
encephalitis, meningitis, or ﬂaccid paralysis. About 80% of WNV
infections are asymptomatic, 20% result in self-limited West Nile
fever, and b1% result in neurologic disease (Hayes and Gubler, 2006).
Host genetic factors might be important to control the susceptibility
and severity to WNV infection (Diamond et al., 2009). Our
laboratories reported that classical inbred strains such as BALB/c,
whose genome is 92% of Mus m. domesticus origin (Yang et al., 2007),
were highly susceptible to intraperitoneal infection with the
neuroinvasive and neurovirulent Israeli strain IS-98-ST1 of WNV
while mouse strains derived from wild progenitors of the M. m.
musculus (MBT/Pas) or Mus spretus (SEG/Pas) species were resistant.
Wemapped the resistance locus to a critical interval of approximately
1 Mb that contains a cluster of 10 members of the Oas gene family
(Oas1a to Oas1h, Oas2 and Oas3) encoding 2′,5′-oligoadenylatesynthetases, and identiﬁed a premature stop codon within exon 4 of
the Oas1b gene, hence encoding a truncated version of OAS1B, lacking
~30% of its C-terminal domain (Mashimo et al., 2002). There was a
perfect correlation among the various inbred strains of mice between
the presence of this mutation and the susceptibility phenotype,
strongly supporting that the truncated Oas1b allele was responsible
for the susceptibility of laboratory mice to infection with the IS-98-
ST1 viral strain. Perelygin et al.(2002) simultaneously identiﬁed the
premature stop codon in C3H/He mice susceptible to infection with
WNV strain Eg101 and showed that viral growth was impaired in
C3H/He ﬁbroblasts expressing a full-length OAS1B protein. In vitro
experiments further demonstrated that expression of full-length
OAS1B protein but not the C-terminally truncated form inhibits WNV
replication inside infected mouse cells (Kajaste-Rudnitski et al., 2006;
Lucas et al., 2003). Together, there is mounting evidence that the OAS
family may play a crucial role in antiviral host immunity to WNV
mediated by type-I interferons (Kristiansen et al., 2011). Consistent
with this ﬁnding, genetic variations in human and horse OAS1 are risk
factors for infectionwith neuropathogenicWNV (Lim et al., 2009; Rios
et al., 2010). To establish that the alteration in the coding sequence of
the Oas1b gene is causative of susceptibility to ﬂaviviruses, Scherbik et
al. (2007a) replaced exons 4 and 5 in the genome of 129/Sv mice with
DNA that corresponds to the MBT/Pas allele and reported that the
Fig. 2. Schematic structure of the endogenous Oas1b gene and CAG::Oas1bMBT
transgene. Structure of the endogenous Oas1b gene of BALB/c (A) and MBT/Pas
(B) mice. Exons 1 to 6 of Oas1b are shown in boxes. Introns are shown by broken lines.
The position of the CGA arginine codon in MBT/Pas mice that is mutated into TGA stop
codon in BALB/c mice is also indicated. The positions of primers used for detecting (RT-
PCR) and measuring (qRT-PCR) Oas1bmRNA are indicated. (C) The transgene contains
the CMV/β-actin (CAG) promoter with β-actin intron and the complete MBT/Pas Oas1b
cDNA and the SV40 polyadenylation sequence (SV40 p(A)).
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ﬂavivirus via the intracranial route.
In addition to the nonsense mutation, several nucleotide sequence
variants have been identiﬁed in the promoter region of theOas1b gene
(Mashimo et al., 2003). Although none of them was consistent with
the pattern of resistance or susceptibility across the inbred strains
tested, we suspected that one or more of the SNPs could alter
activation of Oas1b transcription in response to viral infection. To gain
a better understanding of the molecular basis of Oas1b-mediated
WNV resistance in vivo, we took a complementary approach. A cloned
cDNA corresponding to the Oas1b mRNA expressed in resistant MBT/
Pas mice was introduced by transgenesis to induce constitutive
expression of the full-length coding sequence in an otherwise
susceptible genetic background (BALB/c). We report that up-regula-
tion of a wild-type Oas1b cDNA confers to BALB/c mice resistance
against lethal WNV-induced encephalitis.
Results and discussion
Full-length OAS1B is a key-factor for mouse resistance to WNV infection
Positional cloning identiﬁed Oas1b as a candidate gene accounting
for the resistance of wild-derived inbred strains of mice to infection
with WNV (Mashimo et al., 2002; Perelygin et al., 2002). To further
assess the role of the Oas1b gene during lethal infection, we produced
a C.MBT-Oas1b congenic line where the Oas gene cluster of the MBT/
Pas resistant strain was introgressed into the BALB/c susceptible
genetic background. C.MBT-Oas1b congenic mice survive an i.p.
inoculation of 1000 FFU of the virulent IS-98-ST1 WNV strain while
BALB/c mice die within 10 days post-infection (Fig. 1), indicating that
the MBT/Pas segment carries one or more determinant(s) of
resistance (Mashimo et al., 2002). Although this result demonstrates
the importance of the Oas gene cluster, it does not point unambig-
uously to the Oas1b nonsense mutation.
To address this issue, a transgene consisting of the CAG promoter
and Oas1b cDNA from MBT/Pas strain was constructed (Fig. 2) and
micro-injected into (C57BL/6 J×SJL/J)F2 fertilized eggs. Eggs were
implanted in pseudo pregnant females. Three resulting founder
animals harboured the entire transgene (Tg), as shown by PCR
analysis, and were crossed with BALB/c mice to generate transgenic
lines in a BALB/c genetic background. After twelve generations of
backcrossing, Tg/+ transgenic mice from each of the three lines were
examined for their susceptibility to lethal infectionwithWNV. C.MBT-
Oas1b congenic and BALB/c mice served as controls. Mice were
inoculated i.p. with 1000 FFU of the virulentWNV IS-98-ST1 strain. AllFig. 1. Survival analysis of mice after West Nile virus infection. CAG::Oas1bMBT
transgenic mice from line 1 (N=33), line 2 (N=8) and line 3 (N=22), C.MBT-Oas1b
congenic mice (N=20) and BALB/c control mice (N=20) were inoculated with
1000 FFU of WNV IS-98-ST1 strain via the intraperitoneal route andmonitored daily for
mortality during 14 days. CAG::Oas1bMBT transgenic mice from lines 1, 2 and 3 were
signiﬁcantly more resistant than BALB/c mice (pb10−7, pb10−8 and pb0.005,
respectively).BALB/c mice (N=20) died within 10 days post-infection, whereas all
C.MBT-Oas1b mice (N=20) survived the infection, as expected. In
CAG::Oas1bMBT transgenic line 1, 75.7% (25/33) of the Tg/+ mice
survived the infection (Fig. 1). There was no signiﬁcant sex bias on
survival. Tg/+ mice from transgenic lines 2 and 3 also survived the
infection, though the percentage of survivors was lower (50 and 37%
on average, respectively) (Fig. 1). These data indicate that the CAG::
Oas1bMBT transgene partially rescued the susceptible phenotype of
BALB/c mice.
The CAG composite promoter has been shown to drive transgene
expression in the whole body of adults and in embryos (Kawamoto et
al., 2000; Kubo et al., 2002; Okabe et al., 1997). To assess CAG::
Oas1bMBT transgene expression in vivo, RT-PCR experiments were
performed on various tissues of adult mice from each line. Organs
were harvested and total RNAs were extracted from the heart, lung,
liver, kidney, spleen and brain, RT-PCR assays were performed using
primer pairs speciﬁc for the transgene (primers c–d in Fig. 2C) and the
housekeeping aldolase gene, respectively. Fig. 3 shows that the
transgene was expressed at detectable levels in the heart, lung, and
brain in each line. However, transgene expression level was hardly
detected in the liver in all lines. The CAG::Oas1bMBT expression was
not identical among the three lines suggesting that expression of the
transgene was dependent on the site of integration, as commonly
observed in transgenic mice (De Sepulveda et al., 1995). The more
resistant transgenic line was used in subsequent investigations. To
evaluate the expression of transgenic and endogenous Oas1b genes,
wemeasured Oas1bmRNA levels in peripheral organ (spleen) and the
central nervous system (brain) of BALB/c, C.MBT-Oas1b and CAG::
Oas1bMBT mice using primers that amplify the transcripts from the
endogenous Oas1bMBT and Oas1bBALB/c genes, and from the Oas1bMBT
transgene (primers a-b in Fig. 2). mRNAs containing a premature
translation termination codon, such as Oas1bBALB/c mRNA, are
generally degraded by nonsense-mediated decay (NMD) (Matsuda
et al., 2008). Table 1 shows that, in the spleen, Oas1bmRNA level was
approximately two fold higher in BALB/c than in C.MBT-Oas1b mice
(pb0.05). This suggests that despite the premature translation
termination codon in exon 4 of Oas1b in BALB/c mice, the transcript
Fig. 3. Expression of the Oas1bMBTmRNA in CAG::Oas1bMBT transgenic mice. Agarose gel
showing RT-PCR products generated from total RNA collected from the heart, lung,
liver, kidney, spleen and brain of a mouse from transgenic line 1, line 2 and line 3, and
BALB/c (BALB) inbred line (C). RT-PCR primers were designed to amplify fragments of
the transgene Oas1b cDNA (343 bp) and the endogenous internal control aldolase (Ald)
cDNA (278 bp). M (marker) denotes the low range DNA ladder, 25–700 bp (Fermentas
GmbH, Courtaboeuf, France).
Table 2
Relative levels of expression of Oas1amRNA in the spleen and brain of uninfected wild-
type BALB/c, C.MBT-Oas1b congenic and CAG::Oas1bMBT transgenic mice.
Mice Relative level of Oas1a mRNA
expression in the spleen a
Relative level of Oas1a mRNA
expression in the brain a
BALB/c 1 [0.28–3.55] b 1 [0.27–3.65]
Congenic
C.MBT-Oas1b
0.78 [0.26–2.37] 1.81 [0.47–7.03]
Transgenic
CAG::Oas1bMBT
1.14 [1.52–1.14] 1.27 [0.42–3.79]
a Total RNA from the same mice and organs was analyzed for the expression of Oas1a
mRNA.
b Data are expressed as the relative increase (n-fold) compared with uninfected
BALB/c mice. Average values and 95% conﬁdence intervals for the relative quantization
values are from ten mice.
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detection of Oas1b mRNA in different tissues of BALB/c mice
(Mashimo et al., 2003; Perelygin et al., 2002), and the truncated
form of OAS1B in ﬁbroblasts overexpressing Oas1bBALB/c cDNA
(Kajaste-Rudnitski et al., 2006).Oas1b is likely an additional exception
to the rule for which nonsense codons trigger NMD (Matsuda et al.,
2008). In the brain of transgenic CAG::Oas1bMBT mice, Oas1b mRNA
levels were approximately 1,300 (i.e. 5,814/4.3) and 5,800 fold higher
than in the brain of C.MBT-Oas1b (pb0.001) and BALB/c mice
(pb0.001), respectively. Small signiﬁcant difference in Oas1b mRNA
levels was also observed in the spleen of CAG::Oas1bMBT mice
compared to C.MBT-Oas1b (pb0.01). To determine whether the
expression of other Oas genes was affected by the increase in Oas1b
expression, we measured Oas1a mRNA levels in the spleen and brain
of BALB/c, C.MBT-Oas1b and CAG::Oas1bMBT mice. Table 2 shows that
Oas1a gene was expressed at similar levels in BALB/c, C.MBT-Oas1b
and CAG::Oas1bMBT mice, indicating that increase Oas1b expression
was not associated with variation in Oas1a expression.Table 1
Relative levels of expression of the endogenous and transgenic Oas1bmRNA in the spleen
and brain of uninfected wild-type BALB/c, C.MBT-Oas1b congenic and CAG::Oas1bMBT
transgenic mice.
Mice Expressed Oas1b
gene(s)
Relative level of Oas1b
mRNA expression in
the spleena
Relative level of
Oas1b mRNA
expression in the
braina
BALB/c Endogenous
Oas1bBALB/c gene
1 [0.61–1.64] 1 [0.59–1.71]
Congenic
C. MBT-Oas1b
Endogenous
Oas1bMBT gene
0.41 [0.25–0.66]b 4.3 [2.34–7.77]
Transgenic
CAG::Oas1bMBT
Endogenous
Oas1bBALB/c gene and
Oas1bMBT transgene
1.82 [1.02–3.25] 5814 [4965–6807]c
a Total RNA from the same mice and organs was analyzed for the expression of
endogenous Oas1b mRNA (wild-type BALB/c, and C.MBT-Oas1b mice) and of both
endogenous and transgenic Oas1b mRNA (CAG::Oas1bMBT mice) by qRT-PCR. Data are
expressed as the relative increase (n-fold) compared with uninfected BALB/c mice.
Average values and 95% conﬁdence intervals for the relative quantization values are
from ten mice.
b pb0.05.
c pb0.001.Up-regulation of endogenous Oas1b in response to West Nile virus
infection
Oas1b gene is induced in response to WNV infection in mouse
embryonic ﬁbroblasts (Fredericksen et al., 2008; Scherbik et al.,
2007b). To determine the time course and level of endogenous Oas1b
gene expression in susceptible and resistant mice, we measured the
level of Oas1b mRNA in spleen and brain after lethal infection with
WNV. Susceptible BALB/c, resistant C.MBT-Oas1b, and partially
resistant CAG::Oas1bMBT mice were infected intraperitoneally with
1000 FFU of the virulent WNV IS-98-ST1 strain and Oas1bmRNA was
measured in samples harvested on days 1, 2, 4, 6, 8 and 10 post-
infection by qRT-PCR using primers speciﬁc for the endogenous Oas1b
transcripts (c–d′ in Fig. 2B). In susceptible BALB/c mice that carry a
nonsense mutation in the Oas1b coding sequence, we detected no
signiﬁcant induction of Oas1bBALB/c mRNA in the spleen (Fig. 4A).
However, in the brain, the expression of Oas1bBALB/c mRNA was
increased 12 fold on day 2.Oas1bBALB/cmRNA levels peaked on day 8 in
the brain (200-fold increase, pb0.001) (Fig. 4B), one day before the
death of most infected BALB/c mice (Fig. 1). In resistant C.MBT-Oas1b
mice, with an arginine codon replacing the stop codon in the Oas1b
coding sequence, Oas1bMBT mRNA levels were increased 260 to 600
fold in the spleen on days 1 and 2. At later stages, Oas1bMBT mRNA
levels in the spleen decreased gradually to reach the level seen in
uninfected controls (Fig. 4C). In the brain, the peak induction of
Oas1bMBTmRNA (200-fold increase; pb0.001) was observed on day 4.
Thereafter, Oas1bMBT mRNA levels decreased progressively even
though it still remained high on day 10 post-infection, 15 fold higher
than the level measured in uninfected controls (Fig. 4D). Partially
resistant CAG::Oas1MBT transgenic mice are homozygous for the
Oas1bBALB/c allele. In the spleen of CAG::Oas1MBT mice, Oas1bBALB/c
mRNA levels were moderately increased (7-fold) on day 1 and
decreased progressively thereafter (Fig. 4E). In the brain of CAG::
Oas1MBT mice, the level of Oas1bBALB/c mRNA increased until day 8 (16
fold compared to uninfected controls, Fig. 4F). Altogether, resistant
C.MBT-Oas1b mice were characterized by a signiﬁcant induction of
Oas1bMBT expression in the spleen and brain at an early stage post-
infection. By contrast, the expression of Oas1bBALB/c mRNA was not
signiﬁcantly increased in the spleen of susceptible BALB/c mice. High
levels of Oas1bBALB/c mRNA in the brain at day 8 likely reﬂected very
high viral burden at this late stage of infection preceding death from
encephalitis. These data suggest that susceptibility in BALB/c mice
could result from the combined effects of the nonsense mutation in
the coding sequence and of one or more regulatory mutation(s) in the
promoter region of the BALB/c Oas1b gene (Mashimo et al., 2003).
Expression of mRNA encoding full-length OAS1B in transgenic mice
infected with WNV
Tounderstandhowthe transgenemayprevent lethalWNV infection,
we analyzed the kinetics of expression of Oas1bMBTmRNA in the spleen
Fig. 4. Levels of endogenous Oas1bmRNA expression in the spleen and brain ofWest Nile virus-infected mice. BALB/c (A, B), C.MBT-Oas1b (C, D) and CAG::Oas1bMBT (E, F) mice were
infected with 1000 FFU of the virulent IS-98-ST1 strain and euthanized on days 1, 2, 4, 6, 8 and 10. Total RNA from the spleen (A, C and E) and brain (B, D and F) was analyzed for the
expression of endogenous Oas1b mRNA by qRT-PCR. Data are expressed as the relative increase (n-fold) compared with uninfected controls. Data from ten mice are shown as
whisker-box plots. Open circles indicate outliers.
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infected i.p. with 1000 FFU of WNV IS-98-ST1 strain and Oas1bMBT
mRNAwasmeasured from samples harvested on days 1, 2, 4, 6, 8 and 10
post-infection by qRT-PCR using primers speciﬁc for the transgenic
Oas1bMBT mRNA (c–d in Fig. 2C). In the spleen, transgenic Oas1bMBT
mRNA levels were decreased at an early stage, on days 1 (20 fold) and 2
(approximately 500,000 fold). On later days, Oas1bMBT mRNA levels
were progressively restored to that of uninfected controls (Fig. 5A). In
the brain, Oas1bMBT mRNA levels also dropped off (160 fold) on days 1
and 2, but increased signiﬁcantly thereafter to peak on day 6 post-
infection at 150 fold the level measured in the uninfected controls.
Thereafter, Oas1bMBT mRNA levels decreased progressively to the level
seen in the controls (Fig. 5B). Therefore, induction of the transgenic
Oas1bMBT mRNA in the spleen may not account for the survival of
transgenic BALB/c mice. These data suggest that the high expression of
Oas1bMBT mRNA in the brain prior and after the infection is critical for
the survival of CAG::Oas1bMBT mice.
To evaluate the effect of Oas1b mRNA expression on WNV
infection, we analyzed viral growth kinetics in the brain of infectedBALB/c, C.MBT-Oas1b and CAG::Oas1bMBT mice. Fig. 6 shows that the
viral burden increased signiﬁcantly in BALB/c mice between day 6 and
day 8. The peak of viral burden in the brain of BALB/c mice correlated
with the 200 fold increase of Oas1bBALB/c mRNA expression (Fig. 4B).
By contrast, the viral burden did not vary between day 6 and day 8 in
the brain of C.MBT-Oas1b and CAG::Oas1bMBT mice. These data
suggest that the antiviral effect of Oas1bMBT gene expression
contributes to the increased survival of C.MBT-Oas1b and CAG::Oas1bMBT
mice.
In the present study, we show that inducing constitutive
expression of an Oas1bMBT transgene in an Oas1bBALB/c background is
able to confer resistance to an otherwise lethal infection with WNV.
Our results establish the functional role played by the premature stop
codon in exon 4 of Oas1b gene in the susceptibility of BALB/c mice but
also suggest impaired activation of the Oas1b gene in response to viral
infection in this strain. These ﬁndings are in agreement with in vitro
studies that showed reduce viral production in WNV-infected cells
overexpressing mRNA encoding the full-length OAS1B (Lucas et al.,
2003; Perelygin et al., 2002). In recent studies, Scherbik et al.(2007a)
Fig. 5. Level of CAG::Oas1bMBT mRNA expression in West Nile virus-infected transgenic
mice. Mice were infected with 1000 FFU of the virulent IS-98-ST1 strain and euthanized
on days 1, 2, 4, 6, 8 and 10. Total RNA from the spleen (A) and brain (B) was analyzed for
the expression of transgenic Oas1b mRNA by qRT-PCR. Data are expressed as the
relative increase (n-fold) compared with uninfected controls. Data from ten mice are
shown as whisker-box plots. Open circles indicate outliers.
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replacement of exons 4 and 5 of Oas1b gene in susceptible 129/SvJ
mice by the corresponding sequences from resistant mice results in
the acquisition of resistance to intracerebral infection by the
neurovirulent 17D strain of yellow fever virus. Together, the results
of knock-in and transgenesis experiments establish that expression of
a full-length OAS1B protein is a cornerstone in the resistance to
infection with ﬂaviviruses.
Important for the outcome of the disease in transgenic mice were
the levels of Oas1bMBT mRNA in the brain prior to and after infection.
The 1300 fold increase in Oas1bMBT mRNA level in the brain of
transgenicmice compared to congenicmice prior to infection (Table 1)Fig. 6. Viral burden analysis in the brain of wild-type BALB/c, congenic C.MBT-Oas1b
and transgenic CAG::Oas1bMBTmice afterWest Nile virus infection.West Nile virus RNA
in the brain was determined from samples harvested on days 6 and 8 using qRT-PCR.
Data are shown as viral RNA equivalent of PFU per gram of tissue at the indicated time
point. Data from ten mice are shown as whisker-box plots. *: pb0.05.and the further 150 fold increase at day 6 post-infection (Fig. 5B) were
able to control viral burden in the brain (see Fig. 6). This suggests that
high levels of functionalOAS1B in thebrain of naivemice are protective
towards later WNV infection. These data agree with recent studies
showing that pre-treatment ofmice in vivowithOAS1 protein potently
inhibits viral infection (Kristiansen et al., 2010). Following infection via
the peripheral route, the viral burdenwas not signiﬁcantly lower in the
brain of congenic C.MBT-Oas1b and CAG::Oas1b transgenicmice at day
6 post-infection compared to the viral burden in the brain of BALB/c
mice. This suggests that the expression of full-length OAS1B protein in
peripheral organs of congenic and transgenic mice had no signiﬁcant
effect onWNV replication in peripheral tissues and on the spreading to
the brain. At day 8, a signiﬁcant increase in viral burden was observed
in the brains of BALB/c mice. By contrast, there was no increase in viral
burden in the brain of congenic and transgenic mice. These data
suggest that following infection with a neuroinvasive and neuroviru-
lentWNV strain, OAS1Bprotein is crucial in the brainwhere it is able to
limit the burden of viral genome. Despite this protection by the CAG::
Oas1bMBT transgene, approximately one-third of transgenic mice did
not survive the challenge, indicating that, by contrastwith theMBT/Pas
chromosomal segment carried by congenic mice, the Oas1bMBT
transgene conferred only partial resistance to WNV-infected BALB/c
mice. Although the reasons remain unclear, several differences
between congenic and transgenic mice could account for the disparity
in results. First, by contrast with endogenous Oas1bMBT gene, the
transgene expression driven by the hybrid cytomegalovirus (CMV)
enhancer/chicken β-actin (CAG) promoter was down-regulated in the
spleen and brain at an early stage post-infection. This decrease is most
likely due to inhibition of the CMV immediate early enhancer by the
cytokine response that follows the viral infection. Indeed, cytokines
induced by WNV infection, such as IFN-α and TNF-α (Fredericksen et
al., 2008) have been shown to reduce transgene expression from the
CMV promoter (Gribaudo et al., 1995; Qin et al., 1997). Second, the
activity of the transgene in the brain prior to infection varied from
mouse to mouse. Lower transgene expression could be responsible for
increased susceptibility in individualmice. It is interesting to note that,
on average, susceptible transgenic mice died approximately two days
later than BALB/c mice (10.1±0.5 days for CAG::Oas1bMBT mice and
8.2±0.2 days for BALB/c mice), suggesting that transgenic Oas1bMBT
mRNA could provide some level of protection against the viral
infection to all individuals. Finally, the possibility that, in congenic
mice, there is a contribution to resistance by additional genetic
factors within the Oas cluster is a critical issue that remains to be
investigated.Materials and methods
Virus
The WNV IS-98-ST1 strain was isolated from the cerebellum of a
white stork during the 1998 outbreak in Israel and passaged three
times in a mosquito cell line (Malkinson et al., 2002) before its
characterization in mice (Lucas et al., 2003).Mice
All studies on animals followed the guideline on the ethical use of
animals from the European Community Council Directive of 24
November 1986 (86/609/EEC). Animal experiments were approved
and conducted in accordance with the Institut Pasteur Biosafety
Committee. BALB/cAnNCrl (BALB/c hereafter) mice were purchased
from Charles River France Laboratories (L'Arbresle, France). Congenic
and transgenic mice were produced in the animal facilities at the
Institut Pasteur.
152 D. Simon-Chazottes et al. / Virology 417 (2011) 147–153Mouse infections
Eight- to ten-week-old mice were used in all experiments.
Infection was performed by intraperitoneal inoculation of 1000 FFU
IS-98-ST1 WNV.
Generation of congenic mice
The 1.45 Mb chromosome 5 segment from the MBT/Pas genome
delimited by the D5Mit68 and D5Mit242 markers, that encompasses
27 genes, including the eight Oas1 paralogs, and the Oas2 and Oas3
genes, was introgressed into the BALB/c background following ten
successive backcrosses. Thereafter, mice heterozygous for the MBT/
Pas chromosomal segment were intercrossed to produce homozy-
gotes for the MBT/Pas segment that were maintained by sib mating.
The resulting congenic line is designated C.MBT-Oas1b.
Production of transgenic mice
The Oas1b cDNA from MBT/Pas strain (GenBank: AF466823) was
inserted into a pCAL3 expression vector (Niwa et al., 1991; Xu et al.,
2001) containing the CMV immediate early enhancer, chicken β-actin
promoter with β-actin intron and SV40 (late gene) polyadenylation
sequence. The entire insert with the promoter and coding region,
pCAG::Oas1bMBT, was linearized with PvuI restriction enzymes and
gel-puriﬁed. The puriﬁed fragment was injected into (C57BL/6 J×SJL/
J) F2 fertilized eggs. Incorporation of the transgene was assessed by
PCR analyses of ear DNA. PCR primers for the transgene detection
were as follows: forward primer, 5′AACCATGTTCATGCCTTCTTCT-3′;
reverse primer, 5′-AAGGAACACCACCAGGTCAG-3′. Three transgenic
founders were used to derive three independent congenic strains by
twelve generations of backcrossing onto the BALB/c background. All
transgenic mice used in this study were heterozygous for the
transgene.
Quantiﬁcation of Oas1a and Oas1b mRNA levels by qRT-PCR
Tenmice were used per time point. After extensive cardiac perfusion
with phosphate-buffered saline (PBS), organs were harvested in 1 ml
Trizol® (Invitrogen, Carlsbad, CA, USA) containing 0.4 g of glass beads
(212–300 μm ø, SIGMA) and homogenized for 40 s at 6.0 in FastPrep
Instrument (MP Biochemicals, Illkirch, France). Isolated RNA was
repuriﬁed using an RNeasy® Plus Mini Kit (QIAGEN, Valencia, CA, USA).
cDNA synthesis was performed with 5 μg RNA using RevertAidTM H
Minus First Strand cDNA Synthesis Kit (Fermentas Inc., Glen Burnie, MD,
USA). Five microliters of a 1:10 dilution of cDNAwere used per qRT-PCR
reaction. The cDNA obtained from organs was quantiﬁed by real-time
qRT-PCR using MaximaTM SYBR Green/ROX qPCR Master Mix (Fermen-
tas) in anABI StepOnePlus apparatus (AppliedBiosystems, Carlsbad, CA).
To analyze the relative fold induction of endogenous Oas1b gene and
CAG::Oas1b transgene mRNA, aldolase (Ald) mRNA expression levels
were also determined for normalization by using the CT method (Livak
and Schmittgen, 2001). For Ald mRNA, the forward primer was 5′-
AGCAGAATGGCATTGTACCC-3′ and reverse primer was 5′-ACAG-
GAAAGTGACCCCAGTG-3′. For Oas1b mRNAs, ﬁve primers were
designed: a: 5′-GAGGTGCCGACGGAGGT-3′; b: 5′-TCCAGAT-
GAAGTCTTCCCAAAG-3′; c: 5′-CAGGATGCTCCAGAGTCAGACG-3′; d: 5′-
TGACACCAGACCAACTGGTAA-3′; and d′: 5′-GACAAGAGAAAGCCCA-
CACC-3′. Primers a and b amplify endogenous Oas1b gene and CAG::
Oas1bMBT transgenemRNAs. Primers c and d′ amplify endogenous Oas1b
mRNA. Primers c and d amplify CAG::Oas1bMBT transgene mRNA.
Therefore, primers c–d and c–d′ allow distinguishing the mRNAs from
endogenousOas1b gene and CAG::Oas1bMBT transgene. To analyseOas1a
mRNA expression levels, the following primers were used: forward: 5′-
GGAGGCGGTTGGCTGAAGAGG-3′; reverse: 5′-GAACCACCGTCGGCA-CATCC-3′. Reactions were quantiﬁed in triplicate and data was analyzed
with StepOnePlus software version 2.1 (Applied Biosystems).
Quantiﬁcation of tissue viral burden
Tomonitor viral spread in the brain, positive-strand viral RNA levels
were measured using Taqman qRT-PCR with the Hot Pol® Probe qPCR
Mix (Euromedex, Souffelweyersheim, France). The 5′-end of WNV
capsid mRNA was ampliﬁed from total RNA and its expression level
quantiﬁed. The followingprimers andprobewere used: forwardprimer,
5′-CCTGTGTGAGCTGACAAACTTAGT-3′; reverse primer, 5′-
GCGTTTTAGCATATTGACAGCC-3′; probe, 5′-FAM-CCTGGTTTCTTAGA-
CATCGAGATCT-3′-TAMRA, as previously described (Linke et al., 2007).
Statistical analysis
Data analysis was performed using theMS Excel statistical package
(Microsoft Corporation). Kaplan–Meier survival data was analyzed by
the log rank test. Differences in relative expression were analyzed
using one-way analysis of variance (ANOVA) or non-parametric
Mann–Whitney test.
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